Limits...
Characterization of Prejunctional Muscarinic Receptors: Effects on the Release of VIP and Functional Responses and Receptor Expression in the Ovine Submandibular Gland.

Ryberg AT, Soukup O, Tobin G - Adv Pharmacol Sci (2009)

Bottom Line: While metchoctramine increased the output of protein, pirenzepine inhibited flow of saliva and increased protein output, vasodilatation, and VIP output.In morphological examinations, the inhibitory muscarinic M4 receptor occurred interacinarily in the gland.It is concluded that prejunctional muscarinic receptors, most likely of the M4 subtype, exert inhibitory modulation of the parasympathetic release of VIP in the ovine submandibular gland.

View Article: PubMed Central - PubMed

Affiliation: Department of Pharmacology, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, 405 30 Göteborg, Sweden.

ABSTRACT
In the in vivo experiments on anaesthetized sheep, it was presently examined whether muscarinic receptor antagonists with diverse selectivity affect the release of VIP in response to electrical stimulation of the parasympathetic chorda tympanic nerve differently, and if the changes in the release could be associated to altered secretory and vasodilator responses. The location of the muscarinic receptor subtypes was examined also. In the experiments, blood was collected out of the submandibular venous drainage before and during electrical stimulation of chorda tympani nerve in the absence and presence either of pirenzepine or methoctramine. While metchoctramine increased the output of protein, pirenzepine inhibited flow of saliva and increased protein output, vasodilatation, and VIP output. In morphological examinations, the inhibitory muscarinic M4 receptor occurred interacinarily in the gland. It is concluded that prejunctional muscarinic receptors, most likely of the M4 subtype, exert inhibitory modulation of the parasympathetic release of VIP in the ovine submandibular gland.

No MeSH data available.


Related in: MedlinePlus

Immunohistochemical labelling of submandibular glands. Images demonstrate staining in absence of antibody (a; control); staining in the presence of muscarinic M1 (b), M2 (c), M3 (d), M4 (e), and M5 (f) receptor antibodies. Bar in panels indicates 10 μm.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2990107&req=5

fig2: Immunohistochemical labelling of submandibular glands. Images demonstrate staining in absence of antibody (a; control); staining in the presence of muscarinic M1 (b), M2 (c), M3 (d), M4 (e), and M5 (f) receptor antibodies. Bar in panels indicates 10 μm.

Mentions: In the immunohistochemical examination, all muscarinic receptor subtypes except the M2 receptor were detected in the submandibular acinar tissue (Figure 2). In the glandular stroma, clear staining for the muscarinic M4 receptor appeared. Occaisonally, a vague staining for the muscarinic M1 receptor seems to occur also, but no staining was detected interacinarily for the other subtypes.


Characterization of Prejunctional Muscarinic Receptors: Effects on the Release of VIP and Functional Responses and Receptor Expression in the Ovine Submandibular Gland.

Ryberg AT, Soukup O, Tobin G - Adv Pharmacol Sci (2009)

Immunohistochemical labelling of submandibular glands. Images demonstrate staining in absence of antibody (a; control); staining in the presence of muscarinic M1 (b), M2 (c), M3 (d), M4 (e), and M5 (f) receptor antibodies. Bar in panels indicates 10 μm.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2990107&req=5

fig2: Immunohistochemical labelling of submandibular glands. Images demonstrate staining in absence of antibody (a; control); staining in the presence of muscarinic M1 (b), M2 (c), M3 (d), M4 (e), and M5 (f) receptor antibodies. Bar in panels indicates 10 μm.
Mentions: In the immunohistochemical examination, all muscarinic receptor subtypes except the M2 receptor were detected in the submandibular acinar tissue (Figure 2). In the glandular stroma, clear staining for the muscarinic M4 receptor appeared. Occaisonally, a vague staining for the muscarinic M1 receptor seems to occur also, but no staining was detected interacinarily for the other subtypes.

Bottom Line: While metchoctramine increased the output of protein, pirenzepine inhibited flow of saliva and increased protein output, vasodilatation, and VIP output.In morphological examinations, the inhibitory muscarinic M4 receptor occurred interacinarily in the gland.It is concluded that prejunctional muscarinic receptors, most likely of the M4 subtype, exert inhibitory modulation of the parasympathetic release of VIP in the ovine submandibular gland.

View Article: PubMed Central - PubMed

Affiliation: Department of Pharmacology, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, 405 30 Göteborg, Sweden.

ABSTRACT
In the in vivo experiments on anaesthetized sheep, it was presently examined whether muscarinic receptor antagonists with diverse selectivity affect the release of VIP in response to electrical stimulation of the parasympathetic chorda tympanic nerve differently, and if the changes in the release could be associated to altered secretory and vasodilator responses. The location of the muscarinic receptor subtypes was examined also. In the experiments, blood was collected out of the submandibular venous drainage before and during electrical stimulation of chorda tympani nerve in the absence and presence either of pirenzepine or methoctramine. While metchoctramine increased the output of protein, pirenzepine inhibited flow of saliva and increased protein output, vasodilatation, and VIP output. In morphological examinations, the inhibitory muscarinic M4 receptor occurred interacinarily in the gland. It is concluded that prejunctional muscarinic receptors, most likely of the M4 subtype, exert inhibitory modulation of the parasympathetic release of VIP in the ovine submandibular gland.

No MeSH data available.


Related in: MedlinePlus